# Teclison

Source: https://onco.cc/companies/teclison/  
OnCo record `teclison` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Teclison is a US-based biotechnology company that leads 3 cancer trials in OnCo, testing trans-arterial tirapazamine embolisation (TATE) in hepatocellular carcinoma, neuroendocrine tumours and colorectal cancer.

## Summary

Teclison develops cancer therapies designed to induce tumour necrosis and enhance anti-tumour immunity, with a focus on improving the effect of immune checkpoint inhibitors in solid tumours that have spread to the liver. Its clinical programme is trans-arterial tirapazamine embolisation (TATE), studied alone and with pembrolizumab. It has offices in Princeton and Taipei. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT03259867 (phase 2, Combination of TATE and PD-1 Inhibitor in Liver Cancer), NCT02174549 (phase 1/2, Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer) and NCT04701476 (phase 2, TATE and Pembrolizumab (MK3475) in mCRC and NSCLC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Teclison Ltd.
- Tags: ctgov-sponsor
- HQ: Princeton, New Jersey
- Type: biotech
- Website: https://www.teclison.com/

## Sources

- Official website: https://www.teclison.com/
- ClinicalTrials.gov: trials led by Teclison: https://clinicaltrials.gov/search?lead=Teclison%20Ltd.

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Regorafenib](https://onco.cc/drugs/regorafenib/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- trials: [Combination of TATE and PD-1 Inhibitor in Liver Cancer](https://onco.cc/trials/nct03259867/), [Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer](https://onco.cc/trials/nct02174549/), [TATE and Pembrolizumab (MK3475) in mCRC and NSCLC](https://onco.cc/trials/nct04701476/)

---
JSON: https://onco.cc/api/v1/entities/teclison.json